Canadian stroke best practice recommendations: Secondary prevention of stroke,sixth edition practice guidelines,update 2017

Abstract

The 2017 update of The Canadian Stroke Best Practice Recommendations for the Secondary Prevention of Stroke is a collection of current evidence-based recommendations intended for use by clinicians across a wide range of settings. The goal is to provide guidance for the prevention of ischemic stroke recurrence through the identification and management of modifiable vascular risk factors. Recommendations include those related to diagnostic testing, diet and lifestyle, smoking, hypertension, hyperlipidemia, diabetes, antiplatelet and anticoagulant therapies, carotid artery disease, atrial fibrillation, and other cardiac conditions. Notable changes in this sixth edition include the development of core elements for delivering secondary stroke prevention services, the addition of a section on cervical artery dissection, new recommendations regarding the management of patent foramen ovale, and the removal of the recommendations on management of sleep apnea. The Canadian Stroke Best Practice Recommendations include a range of supporting materials such as implementation resources to facilitate the adoption of evidence to practice, and related performance measures to enable monitoring of uptake and effectiveness of the recommendations. The guidelines further emphasize the need for a systems approach to stroke care, involving an interprofessional team, with access to specialists regardless of patient location, and the need to overcome geographic barriers to ensure equity in access within a universal health care system.

Keywords

Stroke guidelines prevention risk assessment management

Get full access to this article

View all access options for this article.

References

Tracking Heart Disease and Stroke in Canada 2009. http://www.phac-aspc.gc.ca/publicat/2009/cvd-avc/pdf/cvd-avs-2009-eng.pdf (accessed 25 August 2017).

Stroke Stats & Facts. https://ontariostrokenetwork.ca/information-about-stroke/stroke-stats-and-facts/ (accessed 15 June 2017). Ontario Stroke Network, 2016.

Edwards

Kapral

Fang

Swartz

. Long-term morbidity and mortality in patients without early complications after stroke or transient ischemic attack. Can Med Assoc J 2017; 189: E954–E961.

Jewett

Harroud

Hill

et al.

Secondary stroke prevention care services in Canada: resources, capacity, and geographic access. Canadian Medical Association Journal Open 2017; Submitted September 15, 2017.

Sondergaard

Kasner

Rhodes

et al.

Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke. N Engl J Med 2017; 377: 1033–1042.

Mas

Derumeaux

Guillon

et al.

Patent Foramen ovale closure or anticoagulation vs. antiplatelets after stroke. N Engl J Med 2017; 377: 1011–1021.

Saver

Carroll

Thaler

et al.

Long-term outcomes of patent foramen ovale closure or medical therapy after stroke. N Engl J Med 2017; 377: 1022–1032.

McEvoy

Antic

Heeley

et al.

CPAP for prevention of cardiovascular events in obstructive sleep apnea. N Engl J Med 2016; 375: 919–931.

Graham

Harrison

Brouwers

Davies

Dunn

. Facilitating the use of evidence in practice: Evaluating and adapting clinical practice guidelines for local use by health care organizations. J Obstet Gynecol Neonatal Nurs 2002; 31: 599–611.

10.

Vernooij

Alonso-Coello

Brouwers

Martinez Garcia

. Reporting items for updated clinical guidelines: Checklist for the reporting of updated guidelines (CheckUp). PLoS Med 2017; 14: e1002207.

11.

Coutts

Wein

Lindsay

et al.

Canadian Stroke Best Practice Recommendations: Secondary prevention of stroke guidelines, update 2014. Int J Stroke 2015; 10: 282–291.

12.

Casaubon

Boulanger

Blacquiere

et al.

Canadian Stroke Best Practice Recommendations: Hyperacute stroke care guidelines, update 2015. Int J Stroke 2015; 10: 924–40.

13.

Lindsay

MPGG

Bayley

Phillips

Smith

. Canadian stroke best practice recommendations overview and methodology. On behalf of the Canadian Stroke Best Practices Advisory Committee and Writing Groups, Ottawa, ON: Heart and Stroke Foundation, 2014.

14.

Guyatt

Cook

Jaeschke

Pauker

Schunemann

. Grades of recommendation for antithrombotic agents: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 123s–131s.

15.

Casaubon

Boulanger

Glasser

et al.

Canadian Stroke Best Practice Recommendations: Acute inpatient stroke care guidelines, update 2015. Int J Stroke 2016; 11: 239–252.

16.

Johnston

Gress

Browner

Sidney

. Short-term prognosis after emergency department diagnosis of TIA. JAMA 2000; 284: 2901–2906.

17.

Lovett

Dennis

Sandercock

Bamford

Warlow

Rothwell

. Very early risk of stroke after a first transient ischemic attack. Stroke 2003; 34: e138–140.

18.

Thacker

Wiggins

Rice

et al.

Short-term and long-term risk of incident ischemic stroke after transient ischemic attack. Stroke 2010; 41: 239–243.

19.

Hankey

. Secondary stroke prevention. Lancet Neurol 2014; 13: 178–194.

20.

Amarenco

Lavallee

Labreuche

et al.

One-year risk of stroke after transient ischemic attack or minor stroke. N Engl J Med 2016; 374: 1533–42.

21.

Rothwell

Giles

Chandratheva

et al.

Effect of urgent treatment of transient ischaemic attack and minor stroke on early recurrent stroke (EXPRESS study): A prospective population-based sequential comparison. Lancet 2007; 370: 1432–1442.

22.

Hebert

Lindsay

McIntyre

et al.

Canadian stroke best practice recommendations: Stroke rehabilitation practice guidelines, update 2015. Int J Stroke 2016; 11: 459–484.

23.

Feigin

Roth

Naghavi

et al.

Global burden of stroke and risk factors in 188 countries, during 1990-2013: A systematic analysis for the Global Burden of Disease Study 2013. Lancet Neurol 2016; 15: 913–924.

24.

O'Donnell

Chin

Rangarajan

et al.

Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): A case-control study. Lancet 2016; 388: 761–775.

25.

Feng

Hendry

Adams

. Risk of recurrent stroke, myocardial infarction, or death in hospitalized stroke patients. Neurology 2010; 74: 588–593.

26.

Heart & Stroke Foundation Position Statement: Sugar, heart disease and stroke. 2016. https://www.heartandstroke.ca/-/media/pdf-files/canada/2017-position-statements/sugar-ps-eng.ashx (accessed 15 July 2017).

27.

Canadian Physical Activity Guidelines 2011, Canadian Society for Exercise Physiology. http://www.csep.ca/cmfiles/guidelines/canadianphysicalactivityguidelinesstatements_e_2012.pdf (accessed 11 August 2017).

28.

Butt P, Beirness D, Cesa F, Gliksman L, Paradis C and Stockwell T. Alcohol and health in Canada: A summary of evidence and guidelines for low-risk drinking. Ottawa, ON: Canadian Centre on Substance Abuse, 2011.

29.

Rapsomaniki

Timmis

George

et al.

Blood pressure and incidence of twelve cardiovascular diseases: Lifetime risks, healthy life-years lost, and age-specific associations in 1.25 million people. Lancet 2014; 383: 1899–1911.

30.

Law

Morris

Wald

. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: Meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338: b1665.

31.

Musini

Tejani

Bassett

Wright

. Pharmacotherapy for hypertension in the elderly. Cochrane Database Syst Rev 2009; Oct 7(4): Cd000028.

32.

Blood pressure of Canadian children and youth, 2009 to 2011. Statistics Canada, 2012. http://www.statcan.gc.ca/pub/82-625-x/2012001/article/11713-eng.htm (accessed 11 June 2017).

33.

LaRosa

Grundy

Waters

et al.

Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352: 1425–1435.

34.

Mihaylova

Emberson

Blackwell

et al.

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012; 380: 581–590.

35.

Sabatine

Giugliano

Keech

et al.

Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017; 376: 1713–1722.

36.

Anderson

Gregoire

Pearson

et al.

2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. Canadian J Cardiol 2016; 32: 1263–1282.

37.

Group AtCCRiDS. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 2008: 2545–2559.

38.

Duckworth

Abraira

Moritz

et al.

Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360: 129–139.

39.

Marso

Kennedy

House

McGuire

. The effect of intensive glucose control on all-cause and cardiovascular mortality, myocardial infarction and stroke in persons with type 2 diabetes mellitus: A systematic review and meta-analysis. Diab Vasc Dis Res 2010; 7: 119–130.

40.

Zinman

Wanner

Lachin

et al.

Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373: 2117–2128.

41.

Kernan

Viscoli

Furie

et al.

Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med 2016; 374: 1321–1331.

42.

Baigent

Blackwell

Collins

et al.

Aspirin in the primary and secondary prevention of vascular disease: Collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849–1860.

43.

Lin

Liu

et al.

Dual antiplatelet therapy after stroke or transient ischaemic attack–how long to treat? The duration of aspirin plus clopidogrel in stroke or transient ischaemic attack: A systematic review and meta-analysis. Eur J Neurol 2016; 23: 1051–1057.

44.

Wong

Wang

Leng

et al.

Early dual versus mono antiplatelet therapy for acute non-cardioembolic ischemic stroke or transient ischemic attack: An updated systematic review and meta-analysis. Circulation 2013; 128: 1656–1666.

45.

Wachter

Gröschel

Gelbrich

et al.

Holter-electrocardiogram-monitoring in patients with acute ischaemic stroke (Find-AF RANDOMISED): An open-label randomised controlled trial. Lancet Neurol 2017; 16: 282–290.

46.

Gladstone

Spring

Dorian

et al.

Atrial fibrillation in patients with cryptogenic stroke. N Engl J Med 2014; 370: 2467–2477.

47.

Sanna

Diener

H-C

Passman

et al.

Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med 2014; 370: 2478–2486.

48.

Bruins Slot

Berge

. Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation. Cochrane Database Syst Rev 2013; Aug 8(8): Cd008980. doi: 10.1002/14651858.CD008980.pub2.

49.

Kwong

Lam

Y-Y

Yan

C-M

. Bleeding of new oral anticoagulants for stroke prevention in atrial fibrillation: A meta-analysis of randomized controlled trials. Cardiovasc Drugs Ther 2013; 27: 23–35.

50.

Gladstone

Geerts

Douketis

Ivers

Healey

Leblanc

. How to monitor patients receiving direct oral anticoagulants for stroke prevention in atrial fibrillation: A practice tool endorsed by Thrombosis Canada, the Canadian Stroke Consortium, the Canadian Cardiovascular Pharmacists Network, and the Canadian Cardiovascular Society. Ann Intern Med 2015; 163: 382–385.

51.

Heidbuchel

Verhamme

Alings

et al.

EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: Executive summary. Eur Heart J 2013; 34: 2094–2106.

52.

Rerkasem

Rothwell

. Carotid endarterectomy for symptomatic carotid stenosis. Cochrane Database Syst Rev 2011; Apr 13(4): Cd001081. doi: 10.1002/14651858.CD001081.pub2.

53.

Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. JAMA 1995; 273: 1421–1428.

54.

Derdeyn

Chimowitz

Lynn

et al.

Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): The final results of a randomised trial. Lancet 2014; 383: 333–341.

55.

Markus

Hayter

Levi

Feldman

Venables

Norris

. Antiplatelet treatment compared with anticoagulation treatment for cervical artery dissection (CADISS): A randomised trial. Lancet Neurol 2015; 14: 361–367.

56.

Hagen

Scholz

Edwards

. Incidence and size of patent foramen ovale during the first 10 decades of life: An autopsy study of 965 normal hearts. Mayo Clinic Proc 1984; 59: 17–20.

57.

Furlan

Reisman

Massaro

et al.

Closure or medical therapy for cryptogenic stroke with patent foramen ovale. N Engl J Med 2012; 366: 991–999.

58.

Meier

Kalesan

Mattle

et al.

Percutaneous closure of patent foramen ovale in cryptogenic embolism. N Engl J Med 2013; 368: 1083–1091.

59.

Carroll

Saver

Thaler

et al.

Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. N Engl J Med 2013; 368: 1092–1100.

60.

Mas

Arquizan

Lamy

et al.

Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both. N Engl J Med 2001; 345: 1740–1746.

61.

Kent

Dahabreh

Ruthazer

et al.

Device closure of patent foramen ovale after stroke: Pooled analysis of completed randomized trials. J Am Coll Cardiol 2016; 67: 907–917.

62.

Stortecky

da Costa

Mattle

et al.

Percutaneous closure of patent foramen ovale in patients with cryptogenic embolism: A network meta-analysis. Eur Heart J 2015; 36: 120–128.

63.

Amarenco

Davis

Jones

et al.

Clopidogrel plus aspirin versus warfarin in patients with stroke and aortic arch plaques. Stroke 2014; 45: 1248–1257.

64.

Homma

Thompson

Pullicino

et al.

Warfarin and aspirin in patients with heart failure and sinus rhythm. N Engl J Med 2012; 366: 1859–1869.

65.

Homma

Thompson

Sanford

et al.

Benefit of warfarin compared with aspirin in patients with heart failure in sinus rhythm: A subgroup analysis of WARCEF, a randomized controlled trial. Circ Heart Fail 2013; 6: 988–997.

66.

Massie

Collins

Ammon

et al.

Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: The Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial. Circulation 2009; 119: 1616–1624.

67.

Goldstein

Bushnell

Adams

et al.

Guidelines for the primary prevention of stroke: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011; 42: 517–584.

68.

Flossmann

Schulz

Rothwell

. Systematic review of methods and results of studies of the genetic epidemiology of ischemic stroke. Stroke 2004; 35: 212–227.

69.

Dichgans

. Genetics of ischaemic stroke. Lancet Neurol 2007; 6: 149–161.

70.

Traylor

Farrall

Holliday

et al.

Genetic risk factors for ischaemic stroke and its subtypes (the METASTROKE collaboration): A meta-analysis of genome-wide association studies. Lancet Neurol 2012; 11: 951–962.

71.

Jerrard-Dunne

Cloud

Hassan

Markus

. Evaluating the genetic component of ischemic stroke subtypes: A family history study. Stroke 2003; 34: 1364–1369.

72.

Jood

Ladenvall

Rosengren

Blomstrand

Jern

. Family history in ischemic stroke before 70 years of age: The Sahlgrenska Academy Study on Ischemic Stroke. Stroke 2005; 36: 1383–1387.

73.

Schulz

Flossmann

Rothwell

. Heritability of ischemic stroke in relation to age, vascular risk factors, and subtypes of incident stroke in population-based studies. Stroke 2004; 35: 819–824.

74.

Tan

Markus

. Monogenic causes of stroke: Now and the future. J Neurol 2015; 262: 2601–2616.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.42 MB